MSB Trading 2021 - paradigm shift, page-200

You may want to go to another forum to discuss what you want to talk about, about preventing wars, improving water supply or rainfall, about better education, about better access to more vaccines and health care, about funding research into better ways of doing lots of things, like for instance the success in sterilising dengue fever mozzies and reducing Dengue fever that was funded and researched here in Australia.

Just in case you missed it I was discussing pharmaeconomics, bang for buck, in this instance the USA. It was just easier to find British stats.

For new medicines that invariably cost a lot to bring to market. The quoted amount in current times for a medicine that makes it through the testing and BLA process in the USA is about $1B. In many instances it is only after the patent period lapses that these medicines become much cheaper, that might be for the medicine or the production process.

Many countries will take FDA testing as a pretty good benchmark. It just costs a lot more to get through in the USA and there may be other issues at work outside of the actual trial process at work.

And yes older effective medicines are repurposed after testing, that testing has been going on at a rapid rate in the past year for COVID19, and that happens with many diseases.

Now about the ARDS death rate, as in all cause ARDS that Novartis are interested in, the numbers on the web page below, total and % deaths are just the USA, outside of COVID19 ARDS. Globally they might be fairly similar.

https://ardsglobal.org/facts-about-ards-2/